U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H14F3N3O2S
Molecular Weight 369.3632
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEXLANSOPRAZOLE

SMILES

Cc1c(C[S@@](=O)c2[nH]c3ccccc3n2)nccc1OCC(F)(F)F

InChI

InChIKey=MJIHNNLFOKEZEW-RUZDIDTESA-N
InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1

HIDE SMILES / InChI
Molecular Formula C16H14F3N3O2S
Molecular Weight 369.3632
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Dexlansoprazole (trade names Kapidex, Dexilant) is a proton pump inhibitor (PPI) that is marketed by Takeda Pharmaceuticals for the treatment of erosive esophagitis and gastro-oesophageal reflux disease. Dexlansoprazole is used to heal and maintain healing of erosive esophagitis and to treat heartburn associated with gastroesophageal reflux disease (GERD). It lasts longer than lansoprazole, to which it is chemically related, and needs to be taken less often. Dexlansoprazole is supplied for oral administration as a dual delayed-release formulation in capsules and orally disintegrating tablets. The capsules and tablets contain dexlansoprazole in a mixture of two types of enteric-coated granules with different pH-dependent dissolution profiles. The most significant adverse reactions (≥2%) reported in clinical trials were diarrhea, abdominal pain, nausea, upper respiratory tract infection, vomiting, and flatulence.

Originator

Approval Year

1995
184
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
7728
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8043
DEXILANT

Approved Use

DEXILANT is a proton pump inhibitor (PPI) indicated for: •Healing of all grades of erosive esophagitis (EE). (1.1) •Maintaining healing of EE and relief of heartburn. (1.2) •Treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD). (1.3) 1.1 Healing of Erosive Esophagitis DEXILANT is indicated for healing of all grades of erosive esophagitis (EE) for up to eight weeks. 1.2 Maintenance of Healed Erosive Esophagitis DEXILANT is indicated to maintain healing of EE and relief of heartburn for up to six months. 1.3 Symptomatic Non-Erosive Gastroesophageal Reflux Disease DEXILANT is indicated for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks.

Launch Date

1.23327362E12
Curative
Approved
8043
DEXILANT

Approved Use

DEXILANT is a proton pump inhibitor (PPI) indicated for: •Healing of all grades of erosive esophagitis (EE). (1.1) •Maintaining healing of EE and relief of heartburn. (1.2) •Treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD). (1.3) 1.1 Healing of Erosive Esophagitis DEXILANT is indicated for healing of all grades of erosive esophagitis (EE) for up to eight weeks. 1.2 Maintenance of Healed Erosive Esophagitis DEXILANT is indicated to maintain healing of EE and relief of heartburn for up to six months. 1.3 Symptomatic Non-Erosive Gastroesophageal Reflux Disease DEXILANT is indicated for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks.

Launch Date

1.23327362E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1136 ng/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT00847210
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Adolescents
sex:
food status:
691 ng/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT00847210
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Adolescents
sex:
food status:
16.1 (ng/mL)/mg
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT01045096
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
33.5 (ng/mL)/mg
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT01045096
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
37.3 (ng/mL)/mg
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT01045096
15 mg 1 times / day multiple, oral
dose: 15 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
1005 ng/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT01045096
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
559 ng/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT01045096
15 mg 1 times / day multiple, oral
dose: 15 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
964 ng/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT01045096
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
658 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022287s031lbl.pdf
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
1397 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022287s031lbl.pdf
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
143.2 (ng*h/mL)/mg
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT01045096
15 mg 1 times / day multiple, oral
dose: 15 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
55.5 (ng*h/mL)/mg
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT01045096
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
87.6 (ng*h/mL)/mg
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT01045096
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
2149 ng*h/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT01045096
15 mg 1 times / day multiple, oral
dose: 15 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
2628 ng*h/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT01045096
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
3330 ng*h/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT01045096
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
128 (ng*h/mL)/mg
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT01045096
15 mg 1 times / day multiple, oral
dose: 15 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
62 (ng*h/mL)/mg
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT01045096
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
96 (ng*h/mL)/mg
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT01045096
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
1914 ng*h/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT01045096
15 mg 1 times / day multiple, oral
dose: 15 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
2892 ng*h/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT01045096
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
3747 ng*h/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT01045096
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
3275 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022287s031lbl.pdf
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
6529 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022287s031lbl.pdf
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.59 h
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT00847210
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Adolescents
sex:
food status:
1.66 h
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT00847210
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Adolescents
sex:
food status:
Doses

Doses

DosePopulationAdverse events​
30 mg 2 times / day multiple, intravenous
Dose: 30 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 30 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/28138748
healthy, 18-29 years
n = 18
Health Status: healthy
Age Group: 18-29 years
Sex: M+F
Population Size: 18
Sources:
https://pubmed.ncbi.nlm.nih.gov/28138748
Sources:
https://pubmed.ncbi.nlm.nih.gov/28138748
90 mg single, intravenous
Dose: 90 mg
Route: intravenous
Route: single
Dose: 90 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/28138748
healthy, 18-29 years
n = 8
Health Status: healthy
Age Group: 18-29 years
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/28138748
Sources:
https://pubmed.ncbi.nlm.nih.gov/28138748
300 mg single, oral
Highest studied dose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/19826060
healthy, 35 years (range: 18 - 50 years)
n = 36
Health Status: healthy
Age Group: 35 years (range: 18 - 50 years)
Sex: M+F
Population Size: 36
Sources:
https://pubmed.ncbi.nlm.nih.gov/19826060
Sources:
https://pubmed.ncbi.nlm.nih.gov/19826060
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
unhealthy, 48 years (range: 18-90 years)
n = 2218
Health Status: unhealthy
Age Group: 48 years (range: 18-90 years)
Sex: M+F
Population Size: 2218
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Disc. AE: Diarrhea...
AEs leading to
discontinuation/dose reduction:
Diarrhea (0.7%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 35
unhealthy, 48 years (range: 18-90 years)
n = 2218
Health Status: unhealthy
Age Group: 48 years (range: 18-90 years)
Sex: M+F
Population Size: 2218
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 35
Disc. AE: Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Abdominal pain (0.5%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 35
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 35
unhealthy, 48 years (range: 18-90 years)
n = 455
Health Status: unhealthy
Age Group: 48 years (range: 18-90 years)
Sex: M+F
Population Size: 455
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 35
Disc. AE: Diarrhea...
AEs leading to
discontinuation/dose reduction:
Diarrhea (0.2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 35
90 mg 1 times / day steady, oral
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 35
unhealthy, 48 years (range: 18-90 years)
n = 1754
Health Status: unhealthy
Age Group: 48 years (range: 18-90 years)
Sex: M+F
Population Size: 1754
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 35
Disc. AE: Diarrhea, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Diarrhea (0.7%)
Abdominal pain (0.6%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 35
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 36
unhealthy, adult
n = 2311
Health Status: unhealthy
Age Group: adult
Population Size: 2311
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 36
Disc. AE: Dyspepsia, Eructation...
AEs leading to
discontinuation/dose reduction:
Dyspepsia (3 patients)
Eructation (2 patients)
Nausea (6 patients)
Vomiting (6 patients)
Erosive esophagitis (1 patient)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 36
90 mg 1 times / day steady, oral
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 36
unhealthy, adult
n = 2142
Health Status: unhealthy
Age Group: adult
Population Size: 2142
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 36
Disc. AE: Dyspepsia, Eructation...
AEs leading to
discontinuation/dose reduction:
Dyspepsia (1 patient)
Eructation (1 patient)
Nausea (9 patients)
Vomiting (6 patients)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 36
60 mg 2 times / day steady, oral
Overdose
Dose: 60 mg, 2 times / day
Route: oral
Route: steady
Dose: 60 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf
Other AEs: Hypertension...
Other AEs:
Hypertension (serious)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Diarrhea 0.7%
Disc. AE
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
unhealthy, 48 years (range: 18-90 years)
n = 2218
Health Status: unhealthy
Age Group: 48 years (range: 18-90 years)
Sex: M+F
Population Size: 2218
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Abdominal pain 0.5%
Disc. AE
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 35
unhealthy, 48 years (range: 18-90 years)
n = 2218
Health Status: unhealthy
Age Group: 48 years (range: 18-90 years)
Sex: M+F
Population Size: 2218
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 35
Diarrhea 0.2%
Disc. AE
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 35
unhealthy, 48 years (range: 18-90 years)
n = 455
Health Status: unhealthy
Age Group: 48 years (range: 18-90 years)
Sex: M+F
Population Size: 455
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 35
Abdominal pain 0.6%
Disc. AE
90 mg 1 times / day steady, oral
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 35
unhealthy, 48 years (range: 18-90 years)
n = 1754
Health Status: unhealthy
Age Group: 48 years (range: 18-90 years)
Sex: M+F
Population Size: 1754
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 35
Diarrhea 0.7%
Disc. AE
90 mg 1 times / day steady, oral
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 35
unhealthy, 48 years (range: 18-90 years)
n = 1754
Health Status: unhealthy
Age Group: 48 years (range: 18-90 years)
Sex: M+F
Population Size: 1754
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 35
Erosive esophagitis 1 patient
Disc. AE
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 36
unhealthy, adult
n = 2311
Health Status: unhealthy
Age Group: adult
Population Size: 2311
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 36
Eructation 2 patients
Disc. AE
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 36
unhealthy, adult
n = 2311
Health Status: unhealthy
Age Group: adult
Population Size: 2311
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 36
Dyspepsia 3 patients
Disc. AE
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 36
unhealthy, adult
n = 2311
Health Status: unhealthy
Age Group: adult
Population Size: 2311
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 36
Nausea 6 patients
Disc. AE
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 36
unhealthy, adult
n = 2311
Health Status: unhealthy
Age Group: adult
Population Size: 2311
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 36
Vomiting 6 patients
Disc. AE
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 36
unhealthy, adult
n = 2311
Health Status: unhealthy
Age Group: adult
Population Size: 2311
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 36
Dyspepsia 1 patient
Disc. AE
90 mg 1 times / day steady, oral
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 36
unhealthy, adult
n = 2142
Health Status: unhealthy
Age Group: adult
Population Size: 2142
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 36
Eructation 1 patient
Disc. AE
90 mg 1 times / day steady, oral
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 36
unhealthy, adult
n = 2142
Health Status: unhealthy
Age Group: adult
Population Size: 2142
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 36
Vomiting 6 patients
Disc. AE
90 mg 1 times / day steady, oral
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 36
unhealthy, adult
n = 2142
Health Status: unhealthy
Age Group: adult
Population Size: 2142
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 36
Nausea 9 patients
Disc. AE
90 mg 1 times / day steady, oral
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 36
unhealthy, adult
n = 2142
Health Status: unhealthy
Age Group: adult
Population Size: 2142
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf
Page: p. 36
Hypertension serious
60 mg 2 times / day steady, oral
Overdose
Dose: 60 mg, 2 times / day
Route: oral
Route: steady
Dose: 60 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1601

inhibitor
1467
inhibitor
1604
inhibitor
1702

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A1
96

CYP1A2
1383

CYP2A6
627

CYP2B6
717

CYP2C8
818

CYP2E1
790

CYP2C19
1325
CYP2C19
910
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A1
192
 unlikely
CYP2A6
659
 unlikely
CYP2B6
884
 unlikely
CYP2C8
865
 unlikely
CYP2D6
1738
 unlikely
CYP2E1
871
 unlikely
CYP3A4
1772
 unlikely
CYP1A2
1532
 unlikely
no (co-administration study)
Comment: in vivo studies showed that DEXILANT did not have an impact on the pharmacokinetics of coadministered theophylline (CYP1A2 substrate)
Page: 11.0
CYP2C9
1648
 unlikely
no (co-administration study)
Comment: in vivo studies showed that DEXILANT did not have an impact on the pharmacokinetics of coadministered phenytoin (CYP2C9 substrate)
Page: 11.0
CYP2C19
1392
 weak
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
1601
 yes
CYP2C19
910
 yes
yes (pharmacogenomic study)
Comment: mean dexlansoprazole Cmax and AUC values were up to 2 times higher in intermediate compared to extensive metabolizers; in poor metabolizers, mean Cmax was up to 4 times higher and mean AUC was up to 12 times higher compared to extensive metabolizers
Page: 10,12
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
DY521004
https://www.001chemical.com/chem/138530-94-6
AEchem Scientific Corp., USA
AE047759
http://www.aechemsc.com/info_products/AE047759.php
AK Scientific, Inc. (AKSCI)
W0028
http://www.aksci.com/item_detail.php?cat=W0028
AbMole Bioscience
M2627
http://www.abmole.com/products/dexlansoprazole.html
Aceschem
ACF021692
https://www.aceschem.com/catalog/138530-94-6.html
Achemo Scientific Limited
AC-74368
http://www.achemo.com/search/?Keyword= 138530-94-6
Acorn PharmaTech
ACN-046381
http://www.acornpharmatech.com/
Alsachim
890
http://www.alsachim.com/product-C1208-glo.bal-view.html
Ambinter
Amb2444038
http://www.ambinter.com/reference/2444038
Ark Pharm
AK170558
http://www.arkpharminc.com/products/138530-94-6.html
Aurum Pharmatech LLC
Q-1374
http://www.Aurumpharmatech.com/Product/ProductDetails/Q_1374
Chem Scene
CS-2820
http://www.chemscene.com/138530-94-6.html
ChemMol
49420692
http://www.chemmol.com/chemmol/49420692.html
ChemMol
99043051
http://www.chemmol.com/chemmol/99043051.html
Chemenu
CM106762
http://www.chemenu.com/products/CM106762
Chemspace
CSSB00016993951
https://chem-space.com/CSSB00016993951
Combi-Blocks
QC-7636
http://www.combi-blocks.com/cgi-bin/find.cgi?QC-7636
DC Chemicals
DC9092
http://www.dcchemicals.com/product_show-_R_Lansoprazole.html
Hairui
HR111133
http://www.hairuichem.com/en/product/138530-94-6.html
Lab Network
LN01349254
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01349254
MedChem Express
HY-13662B
https://www.medchemexpress.com/_R_-Lansoprazole.html
Molcore
MC521004
https://www.molcore.com/product/138530-94-6
Smolecule
S525777
http://www.smolecule.com/products/s525777
Synblock Inc
PB33188
http://www.synblock.com/product/138530-94-6.html
THE BioTek
bt-267370
https://www.thebiotek.com/product/inhibitors/bt-267370
abcr GmbH
AB455993
http://www.abcr.com/shop/en/AB455993
eNovation Chemicals
D588547
https://www.enovationchem.com/ProductDetails.asp?ProductID=D588547
eNovation Chemicals
D676423
https://www.enovationchem.com/ProductDetails.asp?ProductID=D676423
eNovation Chemicals
D762688
https://www.enovationchem.com/ProductDetails.asp?ProductID=D762688
iChemical
EBD14854
http://www.ichemical.com/products/138530-94-6.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
PubMed

PubMed

TitleDatePubMed
Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.
2002 Jul
Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.
2004 Nov
Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensive metabolizers and treated with tacrolimus.
2006 Dec
Intestinal CYP3A4 is not involved in the enantioselective disposition of lansoprazole.
2006 Jan
Enantioselective disposition of lansoprazole and rabeprazole in human plasma.
2006 Jun
Estimation of the area under the concentration-time curve of racemic lansoprazole by using limited plasma concentration of lansoprazole enantiomers.
2008 May
Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis.
2009
Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development.
2009
New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part II.
2009 Dec
Patents

Patents

06664276
3
06939971
3
06982275
4
07169799
4
07285668
4
07339064
4
07569696
4
07569697
3
07737282
3
07994332
4
08030333
3
08212046
4
08222422
4
08552198
3
08809542
4
JP2001058990A
4
JP2001122783A
3
JP2002114779A
3
JP2003055372A
3
JP2011507977A
3
JP2011513202A
3

Sample Use Guides

In Vivo Use Guide
For erosive esophagitis: One 60 mg capsule once daily for up to 8 weeks Relief of Heartburn: One 30 mg capsule once daily
Route of Administration: Oral
In Vitro Use Guide
A stably transfected gene reporter cell line AZ-AHR, derived from human hepatoma HepG2 cells transfected with a construct containing several AhR binding sites upstream of a luciferase reporter gene, was used for assessment of AhR transcriptional activity. Cells were incubated for 24 h with DEXLANSOPRAZOLE and/or vehicle (DMSO; 0.1% v/v), in the presence or absence of TCDD (10 nM; AZ-AHR cells) or DEX (100 nM; AZ-GR cells). After the treatments, cells were lysed and luciferase activity was measured. In parallel, cell viability was determined by conventional MTT test.
Substance Class Chemical
Created
by admin
on Fri Jun 25 22:03:08 UTC 2021
Edited
by admin
on Fri Jun 25 22:03:08 UTC 2021
Record UNII
UYE4T5I70X
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DEXLANSOPRAZOLE
INN   MART.   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
TAK-390
Code English
1H-BENZIMIDAZOLE, 2-((R)-((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)-2-PYRIDINYL)METHYL)SULFINYL)-
Systematic Name English
DEXILANT
Brand Name English
NSC-758710
Code English
T-168390
Code English
DEXLANSOPRAZOLE [INN]
Common Name English
LANSOPRAZOLE, (R)-
Common Name English
DEXLANSOPRAZOLE [VANDF]
Common Name English
DEXILANT SOLUTAB
Brand Name English
DEXLANSOPRAZOLE [WHO-DD]
Common Name English
KAPIDEX
Brand Name English
2-((R)-((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)-2-PYRIDINYL)METHYL)SULFINYL)-1H-BENZIMIDAZOLE
Systematic Name English
DEXLANSOPRAZOLE [MART.]
Common Name English
LANSOPRAZOLE R-FORM
MI  
Common Name English
LANSOPRAZOLE R-FORM [MI]
Common Name English
(+)-2-((R)-((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)METHYL)SULFINYL)-1H-BENZIMIDAZOLE
Systematic Name English
DEXLANSOPRAZOLE [USAN]
Common Name English
(R)-LANSOPRAZOLE
Common Name English
DEXLANSOPRAZOLE [ORANGE BOOK]
Common Name English
Classification Tree Code System Code
NDF-RT N0000000147
Created by admin on Fri Jun 25 22:03:08 UTC 2021 , Edited by admin on Fri Jun 25 22:03:08 UTC 2021
WHO-VATC QA02BC06
Created by admin on Fri Jun 25 22:03:08 UTC 2021 , Edited by admin on Fri Jun 25 22:03:08 UTC 2021
NCI_THESAURUS C29723
Created by admin on Fri Jun 25 22:03:08 UTC 2021 , Edited by admin on Fri Jun 25 22:03:08 UTC 2021
WHO-ATC A02BC06
Created by admin on Fri Jun 25 22:03:08 UTC 2021 , Edited by admin on Fri Jun 25 22:03:08 UTC 2021
NDF-RT N0000175525
Created by admin on Fri Jun 25 22:03:08 UTC 2021 , Edited by admin on Fri Jun 25 22:03:08 UTC 2021
LIVERTOX 290
Created by admin on Fri Jun 25 22:03:08 UTC 2021 , Edited by admin on Fri Jun 25 22:03:08 UTC 2021
Code System Code Type Description
PUBCHEM
9578005
Created by admin on Fri Jun 25 22:03:08 UTC 2021 , Edited by admin on Fri Jun 25 22:03:08 UTC 2021
PRIMARY
RXCUI
816346
Created by admin on Fri Jun 25 22:03:08 UTC 2021 , Edited by admin on Fri Jun 25 22:03:08 UTC 2021
PRIMARY RxNorm
EVMPD
SUB31929
Created by admin on Fri Jun 25 22:03:08 UTC 2021 , Edited by admin on Fri Jun 25 22:03:08 UTC 2021
PRIMARY
CAS
138530-94-6
Created by admin on Fri Jun 25 22:03:08 UTC 2021 , Edited by admin on Fri Jun 25 22:03:08 UTC 2021
PRIMARY
DRUG BANK
DB05351
Created by admin on Fri Jun 25 22:03:08 UTC 2021 , Edited by admin on Fri Jun 25 22:03:08 UTC 2021
PRIMARY
MERCK INDEX
M6683
Created by admin on Fri Jun 25 22:03:08 UTC 2021 , Edited by admin on Fri Jun 25 22:03:08 UTC 2021
PRIMARY Merck Index
FDA UNII
UYE4T5I70X
Created by admin on Fri Jun 25 22:03:08 UTC 2021 , Edited by admin on Fri Jun 25 22:03:08 UTC 2021
PRIMARY
NCI_THESAURUS
C73192
Created by admin on Fri Jun 25 22:03:08 UTC 2021 , Edited by admin on Fri Jun 25 22:03:08 UTC 2021
PRIMARY
ChEMBL
CHEMBL1201863
Created by admin on Fri Jun 25 22:03:08 UTC 2021 , Edited by admin on Fri Jun 25 22:03:08 UTC 2021
PRIMARY
IUPHAR
5487
Created by admin on Fri Jun 25 22:03:08 UTC 2021 , Edited by admin on Fri Jun 25 22:03:08 UTC 2021
PRIMARY
DRUG CENTRAL
4162
Created by admin on Fri Jun 25 22:03:08 UTC 2021 , Edited by admin on Fri Jun 25 22:03:08 UTC 2021
PRIMARY
LACTMED
Dexlansoprazole
Created by admin on Fri Jun 25 22:03:08 UTC 2021 , Edited by admin on Fri Jun 25 22:03:08 UTC 2021
PRIMARY
INN
8524
Created by admin on Fri Jun 25 22:03:08 UTC 2021 , Edited by admin on Fri Jun 25 22:03:08 UTC 2021
PRIMARY
WIKIPEDIA
DEXLANSOPRAZOLE
Created by admin on Fri Jun 25 22:03:08 UTC 2021 , Edited by admin on Fri Jun 25 22:03:08 UTC 2021
PRIMARY
Related Record Type Details
POTASSIUM-TRANSPORTING ATPASE ALPHA CHAIN 1
TARGET -> INHIBITOR
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Structure of LANSOPRAZOLE
RACEMATE -> ENANTIOMER
Structure of DEXLANSOPRAZOLE SESQUIHYDRATE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of 4-HYDROXY LANSOPRAZOLE SULFIDE
METABOLITE -> PARENT
MINOR
FECAL
Structure of 5-HYDROXYLANSOPRAZOLE SULFONE
METABOLITE -> PARENT
MINOR
FECAL
Structure of LANSOPRAZOLE SULFONE
METABOLITE -> PARENT
In poor metabolizer; mediator: CYP3A
MAJOR
PLASMA
Structure of LANSOPRAZOLE SULFIDE
METABOLITE -> PARENT
Minor in plasma
MAJOR
FECAL
Structure of 5-GLUCURONYLOXY DEXLANSOPRAZOLE SULFIDE
METABOLITE -> PARENT
EM sujects
MAJOR
PLASMA; URINE
Structure of 5-GLUCURONYLOXY DEXLANSOPRAZOLE
METABOLITE -> PARENT
EM Subjects
MAJOR
PLASMA; URINE
Structure of 2-S-N-ACETYLCYSTEINYL BENZIMIDAZOLE
METABOLITE -> PARENT
PM sujects
MAJOR
URINE
Structure of 5-SULFONYLOXY DEXLANSOPRAZOLE SULFIDE
METABOLITE -> PARENT
Extensive metabolizers
MINOR
URINE
Structure of 5-HYDROXYLANSOPRAZOLE, (R)-
METABOLITE -> PARENT
EM Subjects
MAJOR
PLASMA
Structure of 4-SULFONYLOXY LANSOPRAZOLE SULFIDE
METABOLITE -> PARENT
MINOR
FECAL; PLASMA
Structure of 4-SULFONYLOXY DEXLANSOPRAZOLE
METABOLITE -> PARENT
MINOR
PLASMA; URINE
Related Record Type Details
Structure of DEXLANSOPRAZOLE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966